Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Slide Scanner

By Drug Discovery Trends Editor | November 2, 2009

NanoZoomerHamamatsu Corporation has released its next-generation slide scanners, the NanoZoomer 2.0 series. Operating at nearly twice the speed of the original series, the NanoZoomer 2.0 converts a 20 mm x 20 mm area on a glass slide into a 1.9-gigapixel color image in as little as 1 minute 40 seconds. The resulting virtual slides can be conveniently viewed on a computer monitor, shared across computer networks, used for software-aided image analysis in a variety of research applications, and preserved in digital archives. Because the captured image contains nearly two billion pixels, users can magnify specific areas of the image to inspect fine details. The NanoZoomer 2.0 also enables users capture and view multiple focal planes in thick samples (Z-stack scanning).

The NanoZoomer 2.0 is available in two types. The flagship model, NanoZoomer 2.0! -HT, is a fully automated high-throughput scanner that scans up to 210 slides continuously. It is ideal for overnight scanning of large batches of samples. A more compact model, the NanoZoomer 2.0-RS, provides the same high speed and high resolution as the HT model for a smaller number of slides. The RS model handles up to 6 standard slides (76 mm x 26 mm) or 2 double-sized slides (76 mm x 52 mm). Both the HT and RS models can be fitted with an optional fluorescence imaging unit.

The NanoZoomer 2.0 series was introduced at the CAP ’09 meeting in Washington, D.C. Olympus America is a distributor of Hamamatsu’s NanoZoomer 2.0 series in North America.

Hamamatsu Corporation


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50